Terns PharmaceuticalsTERN
TERN
About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
Employees: 66
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
130% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 23
118% more call options, than puts
Call options by funds: $9.7M | Put options by funds: $4.45M
47% more capital invested
Capital invested by funds: $450M [Q2] → $663M (+$213M) [Q3]
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
23% more funds holding
Funds holding: 126 [Q2] → 155 (+29) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
7.94% less ownership
Funds ownership: 102.15% [Q2] → 94.21% (-7.94%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.50
69%
upside
Avg. target
$15.83
256%
upside
High target
$20
349%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
JMP Securities Silvan Tuerkcan 29% 1-year accuracy 16 / 56 met price target | 349%upside $20 | Market Outperform Reiterated | 4 Dec 2024 |
HC Wainwright & Co. Ed Arce 42% 1-year accuracy 68 / 161 met price target | 69%upside $7.50 | Neutral Reiterated | 4 Dec 2024 |
Oppenheimer Jay Olson 22% 1-year accuracy 23 / 104 met price target | 349%upside $20 | Outperform Maintained | 4 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT.
Neutral
GlobeNewsWire
2 weeks ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.
Positive
Market Watch
1 month ago
Terns's stock soars as analysts cheer leukemia data — and predict more gains
The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.
Positive
Market Watch
1 month ago
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial
Terns Pharmaceuticals Inc.'s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.
Neutral
GlobeNewsWire
1 month ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of December 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”).
Positive
Benzinga
2 months ago
Top 3 Health Care Stocks You'll Regret Missing In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
2 months ago
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience
Negative
Market Watch
2 months ago
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.
Neutral
GlobeNewsWire
3 months ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.
Positive
Seeking Alpha
3 months ago
Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected in December 2024, offering another investment opportunity.
Charts implemented using Lightweight Charts™